Cooley M&A

JANUARY 25, 2023

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds. Let’s dig in. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

MergersCorp M&A International

OCTOBER 15, 2024

SPACs are publicly traded companies that raise capital through an initial public offering (IPO) with the primary aim of acquiring an existing private company, thereby enabling it to go public without undergoing the traditional IPO process.

Mergers and Acquisitions 52

Mergers and Acquisitions Advisory IPO Initial Public Offering 52

OfficeHours

OCTOBER 23, 2023

Written by a top OfficeHours Coach; Original article published on October 16, 2023 In today’s world, there is much uncertainty around public markets. However, for private equity investors, this uncertainty represents a unique opportunity to take advantage of investment opportunities in public markets.

Investors 130

Investors Private Equity Equities Investment 130

Razorpay

JULY 27, 2023

Investment banking is a branch of banking that organizes and enables large, complex financial transactions for businesses, like mergers, IPOs or underwriting. Investment Banking Services Initial Public Offering (IPO) When a privately-owned business wants to become a publicly traded company, it goes through an IPO , or Initial Public Offering.

Investment Banking 52

Investment Banking Bank Banking Investment 52

Global Newswire by Notified: M&A

JANUARY 15, 2025

BurTech) (NASDAQ: BRKH), a publicly traded special purpose acquisition company, and Blaize, Inc. and began trading on Nasdaq under the ticker symbols BZAI and BZAIW on January 14, 2025. WASHINGTON and EL DORADO HILLS, Calif., 15, 2025 (GLOBE NEWSWIRE) -- BurTech Acquisition Corp.

Underwriting 40

Underwriting Business Acquisitions IPO 40

OfficeHours

AUGUST 20, 2023

Private equity involves investing capital directly into private businesses that are not publicly traded on stock exchanges (that would be a hedge fund). Once improved, the exit can then take place, usually in the form of another sale or an Initial Public Offering (IPO), both of which are usually under the advice of an investment bank.

Private Equity 130

Private Equity Equities Investment Banking Finance 130

Cooley M&A

MARCH 2, 2021

A SPAC is a publicly traded shell company with no underlying operating business that seeks to merge with a target operating company. According to Nasdaq , in 2015, SPACs made up approximately 12% of the IPO market, but by 2020, that number had risen to approximately 53%. What is a SPAC. Why it matters.

Securities 40

Securities IPO Mergers and Acquisitions Shares 40

Software Equity Group

OCTOBER 22, 2024

In today’s economic climate, retention is everything: Software companies with Net Revenue Retention (NRR) rates above 120% are trading at a remarkable 63% premium over the market median. Because in a world where growth is uncertain, retaining and expanding existing customers is the ultimate competitive advantage.

Valuation 52

Valuation Investors IT Management 52

Cooley M&A

JANUARY 20, 2022

General trends in life sciences M&A. While 2020’s M&A landscape was characterized by whiplash volatility from choppy deal activity in the first half of the year to a surge in volume in the second half, that momentum accelerated in 2021, with no signs of slowing down heading into 2022. driven assets.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 25, 2023

Tech M&A in 2022 was a tale of two halves. 2] Despite the downtrend, global tech M&A activity in 2022 remained strong relative to pre-pandemic levels and accounted for a record 20% of all global M&A activity. Deal volumes dropped from $531.13 billion [1] during the first half of 2022 to $189.17 trillion. [2]

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 22, 2025

Unlike in 2023, when a Q4 dealmaking binge over the holidays led to the sector outperforming the market, life sciences M&A cut down and stuck with it throughout 2024. Unlike in 2023, when a Q4 dealmaking binge over the holidays led to the sector outperforming the market, life sciences M&A cut down and stuck with it throughout 2024.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64